No headlines found.
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission
Globe Newswire (Mon, 15-Dec 8:00 AM ET)
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Globe Newswire (Fri, 14-Nov 8:30 AM ET)
Globe Newswire (Tue, 21-Oct 8:30 AM ET)
Globe Newswire (Wed, 1-Oct 8:05 AM ET)
Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101
Globe Newswire (Wed, 1-Oct 8:00 AM ET)
Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock trades on the NASDAQ stock market under the symbol FBIOP.
As of December 30, 2025, FBIOP stock price climbed to $9.29 with 21,631 million shares trading.
FBIOP has a market cap of $0.00. This is considered a Sub-Micro Cap stock.
In the last 3 years, FBIOP traded as high as $20.35 and as low as $4.72.
FBIOP has outperformed the market in the last year with a return of +35.6%, while the SPY ETF gained +16.7%. However, in the most recent history, FBIOP shares have underperformed the stock market with its stock returning +1.5% in the last 3 month period and -2.2% for the last 2 week period, while SPY has returned +3.8% and +1.2%, respectively.
FBIOP support price is $8.78 and resistance is $9.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FBIOP shares will trade within this expected range on the day.
